Advertisement

Topics

Celgene, Agios Ready For Enasidenib Launch After Early Approval

15:02 EDT 1 Aug 2017 | SCRIP

Idhifa is the first treatment for AML patients with IDH2 mutations. The drug will be co-commercialized by Celgene and Agios...

      

Related Stories

 

Original Article: Celgene, Agios Ready For Enasidenib Launch After Early Approval

NEXT ARTICLE

More From BioPortfolio on "Celgene, Agios Ready For Enasidenib Launch After Early Approval"

Quick Search
Advertisement
 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...